Could oral insulin be the type 2 diabetes treatment of the future?…
Read More »Advanced Glycation End Products (AGEs) and Insulin Sensitivity
Should your patients avoid high heat cooking?…
Read More »Asante Snap Insulin Pump
Asante Snap Insulin Pump Asante Snap’s benefits include: prefilled cartridges, automatically fills tubing (autoprime), 25% lighter than the leading pump, never needs to have the battery changed or charged, uses glass cartridges scientifically proven to keep insulin at high quality, plus first-time users were able to complete critical tasks …
Read More »Insulin Resistance and Body Fat Composition in Type 2 Diabetes
Body fat content more significant than absolute body far amount….
Read More »ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #18: Insulin, Part 3 of 3
Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor Continuous Subcutaneous Insulin Infusion (CSII) PEDIATRICS David Maahs, MD, PhD, and H. Peter Chase, MD Standard of Care A consensus statement on the use of insulin pump therapy, CSII, in youth with type 1 diabetes (T1D) …
Read More »Insulin/Liraglutide Combo in Type 2 Diabetes
A potential new treatment option for T2 diabetes….
Read More »Insulin Glargine U300 versus Lantus
New preliminary data is in…. Sanofi, the maker of Lantus (insulin glargine), finished more phase III studies on their newest formulation of insulin glargine, U300, and discussed their results at the World Diabetes Congress 2013 in early December. The study results have not yet been published but researchers reported that the …
Read More »Insulin Pumps vs. Multiple Daily Injections (MDI): Which is Better?
Can insulin pumps reduce glycemic variability in type 1 diabetes?… A new cross-sectional observational cohort study looked at continuous subcutaneous insulin infusion (CSII), aka insulin pump, versus multiple daily injections (MDI) to determine which insulin delivery system resulted in less blood glucose variability in type 1 pediatric diabetes patients. Large …
Read More »ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #17: Insulin, Part 2 of 3
Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor PEDIATRICS – Jane Lee Chiang, MD, and Georgeanna J. Klingensmith, MD ADULTS – Irl B. Hirsch, MD 1. Basal insulin accounts for ~50% of total daily dose: i. LAA (insulin glargine, detemir, degludec) or NPH if LAA …
Read More »Insulin Initiation in Type 2 Patients
David Joffe, BSPharm, CDE, Editor-in-chief, Diabetes In Control In 2003, the Treat to Target Trial study results were published. The study compared the effectiveness of a patient mediated titration schedule with both NPH and glargine, and also whether patient titration was as good as a prescriber-based titration….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.